Summary statistics - quantitative results

EQA round: RFA2/26 - Risk Factors for Atherosclerosis

Deadline: 2.10.2026

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

RoM = robust average
SD = standard deviation
CV = coefficient of variation
N_{tot} = total number of the results
N_{out} = number of the results removed before calculation
AV = assigned value
CVP = consensus of all participants
CVPG = consensus of the participants' groups
U_{AV} = expanded uncertainty of the assigned value (k = 2)
D_{max} = acceptable difference
LL = lower limit
UL = upper limit
N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
(114) **Apolipoprotein AI**	[g/L]				13								13	11	85
Sample A													13	11	85
(2) Immunoturbidimetry		2,19	0,14	6,2	13	0	CVP	2,15	0,025	17%	1,78	2,52	13		
Sample B													13	13	100
(2) Immunoturbidimetry		1,05	0,071	6,7	13	0	CVP	1,06	0,015	17%	0,879	1,25	13		
(115) **Apolipoprotein B**	[g/L]				15								15	14	93
Sample A													15	14	93
(2) Immunoturbidimetry		1,25	0,071	5,6	15	0	CVP	1,25	0,014	14%	1,07	1,43	15		
Sample B													15	14	93
(2) Immunoturbidimetry		0,632	0,035	5,6	15	0	CVP	0,635	0,007	14%	0,546	0,724	15		
(111) **Cholesterol**	[mmol/L]				38								38	38	100
Sample A													38	38	100
(0) Not specified		6,97	0,22	3,2	38	0	CVP	6,91	0,026	8%	6,35	7,47	38		
Sample B													38	38	100
(0) Not specified		3,42	0,098	2,9	38	0	CVP	3,4	0,014	8%	3,12	3,68	38		
(113) **Cholesterol HDL**	[mmol/L]				38								38	38	100
Sample A		1,95	0,074	3,8	38		CVP	1,96	0,013	15%	1,66	2,26	38	38	100
(2) Direct determination		1,96	0,073	3,7	37	0							37		
Other					1	0							1		
							1x 1								
Sample B		0,949	0,038	4	38		CVP	0,958	0,005	15%	0,814	1,11	38	38	100
(2) Direct determination		0,951	0,037	3,9	37	0							37		
Other					1	0							1		
							1x 1								
(118) **Cholesterol LDL (direct determination)**	[mmol/L]				35								35	35	100
Sample A													35	35	100
(0) Not specified		4,08	0,31	7,5	35	0	CVP	4,06	0,056	20%	3,24	4,88	35		
Sample B													35	35	100
(0) Not specified		2,02	0,13	6,2	35	0	CVP	2,03	0,023	20%	1,62	2,44	35		
(116) **Cholesterol LDL (calculation)**	[mmol/L]				7								7	7	100
Sample A													7	7	100
(0) Not specified		4,1	0,13	3,3	7	0	CVP	4,09	0,04	15%	3,47	4,71	7		
Sample B													7	7	100
(0) Not specified		1,99	0,12	6	7	0	CVP	1,99	0,026	15%	1,69	2,29	7		
(117) **Lipoprotein (a) [g/L]**	[g/L]				4								4	4	100
Sample A		0,32	0,045	14	4		CVP	0,325	0,009	25%	0,243	0,407	4	4	100
Other					4	0							4		
							4x 2								
Sample B		0,185	0,013	6,8	4		CVP	0,167	0,008	25%	0,125	0,209	4	4	100
Other					4	0							4		
							4x 2								
(119) **Lipoprotein (a) [nmol/L]**	[nmol/L]				8								8	7	88
Sample A		65,2	9,3	14	8								8	7	88
(2) Immunoturbidimetry; (60) Roche		59,5	0,82	1,4	5	0	CVPG	58,6	1,7	16%	49,2	68	5		
Other					3	0							3		
							3x 2								
Sample B		28,7	5	18	8								8	7	88
(2) Immunoturbidimetry; (60) Roche		26,2	1,3	4,8	5	0	CVPG	24,8	1,1	16%	20,8	28,8	5		
Other					3	0							3		
							3x 2								
(112) **Triacylglycerols**	[mmol/L]				38								38	38	100
Sample A		2,03	0,066	3,3	38		CVP	2,04	0,008	13%	1,77	2,31	38	38	100
(1) Photometric enzyme (GPO-PAP)		2,03	0,067	3,3	35	0							35		
Other					3	0							3		
							3x 2								
Sample B		1,03	0,038	3,7	38		CVP	1,04	0,006	13%	0,904	1,18	38	38	100
(1) Photometric enzyme (GPO-PAP)		1,03	0,039	3,7	35	0							35		
Other					3	0							3		
							3x 2								